Fosbretabulin disodium
A derivative of combretastatin that acts as a microtubule destabilising agent; damage the vasculature (blood vessels) of cancer tumours causing central necrosis.Chemotherapeutic Agents Phase 3 Clinical (In Vitro) :Fosbretabulin disodium inhibits growth of leukemia P-388, pancreas BXPC-3, neuroblast SK-N-SH, thyroid SW1736, lung-NSC NCI-H460, prostate DU-145, an pharynx FADU, with EC50s of 0.0029, 0.23, 0.00025, 0.00061, 0.00035, 0.00072, and 0.00045 μg/mL, respectively. (In Vivo) :Fosbretabulin disodium (100 mg/kg; i.p.) increases the mean arterial blood pressure (MABP) at 1 and 6 h after administration and decreases the tumor blood flow in rats.
Product Specifications
CAS Number
168555-66-6
Product Name Alternative
CA4DP | CA4P | Combretastatin A-4 phosphate
Purity
>98% (HPLC)
Solubility
H2O: 4.4 mg/mL (Need ultrasonic and warming) ; DMSO: < 0.044 mg/mL
Smiles
COC1=C (C=C (C=C1) /C=C\C2=CC (=C (C (=C2) OC) OC) OC) OP (=O) ([O-]) [O-].[Na+].[Na+]
Molecular Formula
C18H19Na2O8P
Molecular Weight
440.292
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Phenol, 2-methoxy-5-[ (1Z) -2- (3,4,5-trimethoxyphenyl) ethenyl]-, 1- (dihydrogen phosphate), sodium salt (1:2)
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
